8-K: Kodiak Sciences Reports Third Quarter 2024 Results and Provides Clinical Program Updates

Kodiak Sciences announced its third quarter 2024 financial results and provided updates on its clinical programs, including the progress of tarcocimab, KSI-501, and KSI-101.

Summary

• Kodiak Sciences reported a net loss of $43.9 million, or $0.84 per share, for the third quarter of 2024, compared to a net loss of $50.0 million, or $0.95 per share, for the same period in 2023.
• The company's cash and cash equivalents totaled $197.9 million at the end of the third quarter of 2024, which they believe will fund operations into 2026.
• Research and development expenses were $31.9 million for the third quarter of 2024, down from $36.2 million in the same quarter of 2023.
• General and administrative expenses were $14.8 million for the third quarter of 2024, compared to $18.3 million for the third quarter of 2023.
• The company hosted an Investor R&D Day in New York, presenting new clinical data on tarcocimab, which showed an ocular half-life of 20 days, 3-times longer than faricimab and 2to 3-times longer than aflibercept.
• Kodiak is enrolling patients in the Phase 3 GLOW2 study for diabetic retinopathy and the Phase 3 DAYBREAK study for wet AMD, both designed to assess the efficacy and durability of tarcocimab and KSI-501.
• The company is also enrolling patients in the Phase 1b APEX study for KSI-101, a bispecific antibody for macular edema secondary to inflammation, with plans to select two dose levels for Phase 2b/3 studies in the second quarter of 2025.
• Kodiak aims to complete enrollment for the GLOW2 and DAYBREAK studies in the first half of 2025, with topline data expected 48 weeks later.
• If successful, Kodiak plans to file a single Biologics License Application (BLA) for three diseases (wet AMD, retinal vein occlusion, and diabetic retinopathy) based on data from five successful Phase 3 studies with tarcocimab.

Sentiment

Score: 8

Explanation: The document presents a positive outlook with strong clinical data, a solid cash position, and a clear path forward for its clinical programs. The company is making good progress and has a strong pipeline.

Positives

• Tarcocimab's extended half-life of 20 days is a significant improvement over existing treatments.
• The GLOW2 study design mirrors the successful GLOW1 study, increasing the likelihood of positive results.
• The DAYBREAK study is designed to maximize the probability of meeting its primary endpoint.
• KSI-501 has shown potential as a disease-modifying therapy in preclinical models.
• KSI-101 targets a new market segment with no approved therapies other than steroids.
• The company has a strong cash position to support operations into 2026.

Negatives

• The company reported a net loss of $43.9 million for the third quarter of 2024.
• Research and development expenses, while down from the previous year, remain substantial at $31.9 million for the quarter.
• The company is still in the clinical trial phase, and there is no guarantee of regulatory approval for any of its product candidates.

Risks

• The success of the ongoing clinical studies is not guaranteed, and results may not meet expectations.
• Regulatory approval for tarcocimab, KSI-501, and KSI-101 is not assured.
• The company's financial performance is dependent on the success of its clinical programs.
• Adverse conditions in the general domestic and global economic markets could impact the business and operations.
• There is a risk that the new formulations of tarcocimab and KSI-501 may not provide the expected benefits.

Future Outlook

Kodiak anticipates completing enrollment for the GLOW2 and DAYBREAK studies in the first half of 2025 and plans to file a single BLA for three diseases based on five successful Phase 3 studies with tarcocimab. They also expect to select two dose levels for KSI-101 in the second quarter of 2025 and activate the PEAK and PINNACLE studies.

Management Comments

• Victor Perlroth, M.D., Chief Executive Officer, stated that the Investor R&D Day provided a comprehensive overview of Kodiak's current position and future direction, referring to it as 'Kodiak 2.0'.
• Dr. Perlroth highlighted the potential of tarcocimab and KSI-501 in the anti-VEGF market due to their enhanced formulations and durability.
• Dr. Perlroth noted the commercial opportunity and high unmet need for KSI-101 in the macular edema inflammation market.
• Dr. Pablo Velazquez-Martin, Chief Medical Officer, mentioned seeing meaningful clinical responses in patients with macular edema secondary to inflammation in the APEX study.
• Dr. Velazquez-Martin expressed pleasure with the growing enthusiasm and momentum from patients, retina specialists, and clinical practices.

Industry Context

This announcement comes as the retinal disease treatment market is seeing a push for more durable and effective therapies. Kodiak's focus on extended durability and multi-specific targeting aligns with the industry's trend towards addressing unmet needs in retinal vascular diseases and inflammatory conditions.

Comparison to Industry Standards

• Tarcocimab's 20-day ocular half-life is significantly longer than the 7-day half-life of faricimab and the 7-10 day half-life of aflibercept, potentially reducing the frequency of injections.
• The GLOW2 study design, mirroring the successful GLOW1 study, suggests a higher probability of success compared to novel trial designs.
• The DAYBREAK study's individualized dosing approach for tarcocimab reflects real-world clinical practice, potentially leading to better outcomes than fixed-dose regimens.
• KSI-501's dual inhibition of VEGF and IL-6 is a novel approach compared to existing anti-VEGF monotherapies, potentially offering improved efficacy.
• KSI-101 targets a market segment with no approved biologic therapies, presenting a unique opportunity compared to competitors focused on anti-VEGF treatments.

Stakeholder Impact

• Shareholders may be positively impacted by the progress of clinical programs and the company's strong cash position.
• Employees may be motivated by the company's advancements and future prospects.
• Patients may benefit from the development of new and more effective treatments for retinal diseases.
• Suppliers and creditors may have increased confidence in the company's financial stability.

Next Steps

• Complete enrollment for the Phase 3 GLOW2 and DAYBREAK studies in the first half of 2025.
• Present emerging APEX data in MESI patients in the first and second quarters of 2025.
• Select two dose levels for KSI-101 in the second quarter of 2025 and activate the twin PEAK and PINNACLE pivotal studies.
• File a single Biologics License Application (BLA) for three diseases based on five successful Phase 3 studies with tarcocimab.

Key Dates

Keywords

tarcocimab, KSI-501, KSI-101, diabetic retinopathy, wet AMD, macular edema, clinical trials, ABC Platform, biologics, retinal diseases